JOHNSON & JOHNSON — Director's Dealing 2020

Jul 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Fusion Pharmaceuticals Inc. (FUSN)
CIK: 0001805890
Period of Report: 2020-06-30

Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: Johnson & Johnson Innovation - JJDC, Inc. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-30	Common Shares	C	2945516	—	Acquired	2945516	Indirect
2020-06-30	Common Shares	P	725000	$17.00	Acquired	3670516	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-30	Class A Preferred Shares	$	C	10666667	Disposed		Common Shares (1997876)	Indirect
2020-06-30	Class B Preferred Shares	$	C	5059460	Disposed		Common Shares (947640)	Indirect
2020-06-30	Warrants to purchase Class B Preferred Shares	$	C	475802	Disposed		Class B Preferred Shares (475802)	Indirect
2020-06-30	Warrants to purchase Common Shares	$	C	89118	Acquired		Common Shares (89118)	Indirect

Footnotes

F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.

F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.